Psoriatic Arthritis Resource Center

keenan, autoimmune, tofacitinib, telemedicine, covid-19, Hydroxychloroquine, Secukinumab, interview, rheumatologists, rheumatologist, arthroplasty, arthritis, rheumatic, ixekizumab, RA, rheumatoid, FDA, Rheum Round-up: Five RA Drugs Compared, Two THA Approaches, and more

Rheum Round-up: Interview with Dr. Keenan, Rixutimab Ups Severe COVID-19 Risk, PsA Drug Comparison

This week in the DocWire News rheumatology section, I interviewed Robert Keenan, MD, an adjunct associate professor at Duke University School of Medicine, Division...
Adalimumab, Upadacitinib Effective in RA Patients with Inadequate Methotrexate Response

Upadacitinib versus Adalimumab: How Do These Arthritis Drugs Compare?

A higher dose of upadacitinib was superior to adalimumab in patients with psoriatic arthritis, according to a study, but outcomes did not largely differ...
Psoriasis, psoriatic, hydroxychloroquine, RA, ACR, vitamin, vitamins, Rheum Round-up: Interviews with Authors of ‘Untold Stories’ of Female Surgeons, and more

Rheum Round-up: Psoriatic Arthritis Medication Research, Hip Fracture Survival

Guselkumab Safe, Effective in Biologic-naïve Patients with Psoriatic Arthritis Guselkumab was a safe and effective treatment for biologic-naïve patients with psoriatic arthritis (PsA), according to...
guselkumab, ixekizumab, sleep disturbance, sleep, PsA, skin, psoriatic arthritis, Bimekizumab Safe and Effective Treatment for Active Psoriatic Arthritis, Secukinumab, American College of Rheumatology and National Psoriasis Foundation Issue Joint PsA Guidelines

Guselkumab Safe, Effective in Biologic-naïve Patients with Psoriatic Arthritis

Guselkumab was a safe and effective treatment for biologic-naïve patients with psoriatic arthritis (PsA), according to one-year data from a phase 3 study. “Guselkumab, a...
guselkumab, ixekizumab, sleep disturbance, sleep, PsA, skin, psoriatic arthritis, Bimekizumab Safe and Effective Treatment for Active Psoriatic Arthritis, Secukinumab, American College of Rheumatology and National Psoriasis Foundation Issue Joint PsA Guidelines

Ixekizumab Withdrawal In Psoriatic Arthritis May Result In Relapse

Patients with psoriatic arthritis (PsA) who achieved minimal disease activity on ixekizumab may relapse if they terminate treatment, according to a study. SPIRIT-P3, a multicenter,...
Adalimumab, ixekizumab, Humira® No. 1 Drug Linked to $5.1 B Increase in Medical Spending

Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?

An analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported outcomes (PROs) in patients with moderate‐to‐severe chronic plaque psoriasis (PsO),...
Which Arthritis Treatments Increase The Risk for COVID-19?

Which Arthritis Treatments Increase The Risk for COVID-19?

Glucocorticoids in the treatment of arthritis may increase the risk for COVID-19 infection, while targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs) may reduce the risk, according...

Curated Journal Reading List